• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高表达 CC 趋化因子受体 7 可改善肺腺癌患者的术后预后。

High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.

机构信息

Department of Thoracic Disease, Chiba Cancer Center, 662-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan.

出版信息

Br J Cancer. 2013 Sep 3;109(5):1100-8. doi: 10.1038/bjc.2013.440. Epub 2013 Aug 6.

DOI:10.1038/bjc.2013.440
PMID:23922113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3778295/
Abstract

BACKGROUND

Chemokines and chemokine receptors not only have significant roles in cancer metastasis and tumorigenesis but also act as antitumour agents. The interaction between the Crk-like adaptor protein (CrkL), which is encoded by the CRKL gene, and non-receptor tyrosine kinase c-ABL is reported to transform many cells into malignant cells. We examined the effects of CC chemokine receptor 7 (CCR7), CCR7 ligands and CrkL and c-ABL in lung adenocarcinoma.

METHODS

One hundred and twenty patients with lung adenocarcinoma were included in this historical cohort analysis. We examined CCR7 and CCR7 ligands and CrkL and c-ABL mRNA expressions in surgically resected lung adenocarcinoma specimens and evaluated their contribution to prognosis, and the relationship with epidermal growth factor receptor (EGFR) and TP53 mutations.

RESULTS

High CCR7 mRNA expressions indicated better prognoses than those of the groups with low CCR7 mRNA expressions (P=0.007, HR=2.00, 95% CI of ratio: 1.22 -3.31). In lung adenocarcinoma, CrkL and c-ABL mRNAs were related to CCR7 mRNA expression (P<0.0001). CrkL and c-ABL mRNA expressions were influenced by EGFR mutations. A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma.

CONCLUSION

We propose that CCR7 and CCL19 are clinically good prognostic factors and that CCR7 is strongly related to CrkL and c-ABL kinase mRNA expression in lung adenocarcinoma.

摘要

背景

趋化因子和趋化因子受体不仅在癌症转移和肿瘤发生中具有重要作用，而且还可以作为抗肿瘤剂。Crk 样衔接蛋白 (CrkL) 的编码基因 CRKL 与非受体酪氨酸激酶 c-ABL 的相互作用被报道可以将许多细胞转化为恶性细胞。我们研究了 C 型趋化因子受体 7 (CCR7)、CCR7 配体和 CrkL 和 c-ABL 在肺腺癌中的作用。

方法

我们对 120 例肺腺癌患者进行了回顾性队列分析。我们检测了手术切除的肺腺癌标本中 CCR7 和 CCR7 配体以及 CrkL 和 c-ABL 的 mRNA 表达，并评估了它们对预后的影响，以及与表皮生长因子受体 (EGFR) 和 TP53 突变的关系。

结果

高 CCR7 mRNA 表达组的预后优于低 CCR7 mRNA 表达组（P=0.007，HR=2.00，95%CI 比：1.22-3.31）。在肺腺癌中，CrkL 和 c-ABL mRNA 与 CCR7 mRNA 表达相关（P<0.0001）。CrkL 和 c-ABL mRNA 表达受 EGFR 突变的影响。CCL19 的高表达是肺腺癌的良好预后因素。

结论

我们提出 CCR7 和 CCL19 是临床预后良好的因素，并且 CCR7 在肺腺癌中与 CrkL 和 c-ABL 激酶 mRNA 表达密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/b5d896b6258d/bjc2013440f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/7912cda6d9e0/bjc2013440f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/3ca70f6f42b2/bjc2013440f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/4bc81f514eb5/bjc2013440f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/0af662d512ee/bjc2013440f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/d22a84be9eec/bjc2013440f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/b5d896b6258d/bjc2013440f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/7912cda6d9e0/bjc2013440f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/3ca70f6f42b2/bjc2013440f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/4bc81f514eb5/bjc2013440f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/0af662d512ee/bjc2013440f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/d22a84be9eec/bjc2013440f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/597e/3778295/b5d896b6258d/bjc2013440f6.jpg

相似文献

1
High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.高表达 CC 趋化因子受体 7 可改善肺腺癌患者的术后预后。
Br J Cancer. 2013 Sep 3;109(5):1100-8. doi: 10.1038/bjc.2013.440. Epub 2013 Aug 6.
2
Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.Crk样衔接蛋白通过上皮性卵巢癌中的ERK信号通路调节CCL19/CCR7介导的上皮-间质转化。
Med Oncol. 2015 Mar;32(3):47. doi: 10.1007/s12032-015-0494-1. Epub 2015 Jan 31.
3
An assessment of the relationship between the expression of CCR7/CCL19 axis and selected regulatory miRNAs in non-small cell lung cancer.评估 CCR7/CCL19 轴与非小细胞肺癌中选定的调节 miRNA 之间的关系。
Mol Biol Rep. 2019 Oct;46(5):5389-5396. doi: 10.1007/s11033-019-04993-3. Epub 2019 Aug 28.
4
CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma.CC趋化因子受体样1通过损害肝细胞癌中与CCR7相关的趋化作用发挥肿瘤抑制功能。
J Pathol. 2015 Mar;235(4):546-58. doi: 10.1002/path.4450. Epub 2014 Dec 18.
5
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.CRKL 扩增诱导人类非小细胞肺癌的转化和表皮生长因子受体抑制剂耐药性。
Cancer Discov. 2011 Dec;1(7):608-25. doi: 10.1158/2159-8290.CD-11-0046. Epub 2011 Oct 17.
6
Construction of ceRNA prognostic model based on the CCR7/CCL19 chemokine axis as a biomarker in breast cancer.基于 CCR7/CCL19 趋化因子轴作为乳腺癌生物标志物的 ceRNA 预后模型的构建。
BMC Med Genomics. 2023 Oct 21;16(1):254. doi: 10.1186/s12920-023-01683-9.
7
Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.异常的大肿瘤抑制因子2（LATS2）基因表达与肺腺癌中的表皮生长因子受体（EGFR）突变及生存情况相关。
Lung Cancer. 2014 Aug;85(2):282-92. doi: 10.1016/j.lungcan.2014.05.025. Epub 2014 Jun 16.
8
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.表皮生长因子受体基因突变的厄洛替尼治疗的非小细胞肺癌患者中 BRCA1、LMO4 和 CtIPmRNA 的表达。
J Thorac Oncol. 2013 Mar;8(3):295-300. doi: 10.1097/JTO.0b013e31827db621.
9
ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.ANCCA 蛋白表达是手术切除的肺腺癌中一种新的独立预后不良标志物。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S577-82. doi: 10.1245/s10434-013-3027-1. Epub 2013 Jun 18.
10
Chemokine (C‑C motif) ligand 21/C‑C chemokine receptor type 7 triggers migration and invasion of human lung cancer cells by epithelial‑mesenchymal transition via the extracellular signal‑regulated kinase signaling pathway.趋化因子（C-C基序）配体21/C-C趋化因子受体7通过细胞外信号调节激酶信号通路诱导上皮-间质转化，从而触发人肺癌细胞的迁移和侵袭。
Mol Med Rep. 2017 Jun;15(6):4100-4108. doi: 10.3892/mmr.2017.6534. Epub 2017 May 2.

引用本文的文献

1
Comprehensive analysis of regulatory B Cell related genes in prognosis and therapeutic response in lung adenocarcinoma.肺腺癌中调节性B细胞相关基因在预后和治疗反应中的综合分析
Front Immunol. 2025 Jul 30;16:1595408. doi: 10.3389/fimmu.2025.1595408. eCollection 2025.
2
Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103 IL-12-producing dendritic cells and priming CD8 T cells without involving draining lymph nodes.使用表达CCL19的同种异体间充质干细胞进行局部细胞治疗，通过聚集产生白细胞介素-12的CD103树突状细胞和启动CD8 T细胞来发挥强大的抗肿瘤作用，且不涉及引流淋巴结。
J Immunother Cancer. 2024 Dec 10;12(12):e009683. doi: 10.1136/jitc-2024-009683.
3

本文引用的文献

1
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.CRKL 扩增诱导人类非小细胞肺癌的转化和表皮生长因子受体抑制剂耐药性。
Cancer Discov. 2011 Dec;1(7):608-25. doi: 10.1158/2159-8290.CD-11-0046. Epub 2011 Oct 17.
2
STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.STAP-2 与 BCR-ABL 介导的肿瘤发生相互作用并调节其活性。
Oncogene. 2012 Oct 4;31(40):4384-96. doi: 10.1038/onc.2011.604. Epub 2012 Jan 9.
3
Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.
MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma.
MIS18A上调促进肺腺癌的细胞活力、迁移和肿瘤免疫逃逸。
Oncol Lett. 2024 Jun 13;28(2):376. doi: 10.3892/ol.2024.14509. eCollection 2024 Aug.
4
Targeting innate immune pathways for cancer immunotherapy.针对癌症免疫疗法的固有免疫途径。
Immunity. 2023 Oct 10;56(10):2206-2217. doi: 10.1016/j.immuni.2023.07.018. Epub 2023 Sep 12.
5
MRPL12 Acts as A Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung Adenocarcinoma.MRPL12 作为一种新型的预后生物标志物，参与肺腺癌的免疫细胞浸润和肿瘤进展。
Int J Mol Sci. 2023 Feb 1;24(3):2762. doi: 10.3390/ijms24032762.
6
LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.LINC02126 是肺腺癌潜在的诊断、预后和免疫治疗靶点。
BMC Pulm Med. 2022 Nov 10;22(1):412. doi: 10.1186/s12890-022-02215-4.
7
Determination of a prediction model for therapeutic response and prognosis based on chemokine signaling-related genes in stage I-III lung squamous cell carcinoma.基于趋化因子信号相关基因的I-III期肺鳞状细胞癌治疗反应和预后预测模型的确定。
Front Genet. 2022 Aug 31;13:921837. doi: 10.3389/fgene.2022.921837. eCollection 2022.
8
Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的免疫浸润特征及与免疫浸润相关的基因预后特征
Front Genet. 2022 May 2;13:848841. doi: 10.3389/fgene.2022.848841. eCollection 2022.
9
CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: a comprehensive analysis based on TCGA database.CCL19 有望成为乳腺癌的潜在预后生物标志物和肿瘤免疫微环境（TIME）调节剂：基于 TCGA 数据库的综合分析。
Aging (Albany NY). 2022 May 12;14(9):4158-4175. doi: 10.18632/aging.204081.
10
C-C Chemokine Receptor 7 in Cancer.C-C 趋化因子受体 7 在癌症中的作用。
Cells. 2022 Feb 14;11(4):656. doi: 10.3390/cells11040656.
检测怀疑患有癌性脑膜炎的肺腺癌患者脑脊液中的表皮生长因子受体突变。
J Thorac Oncol. 2011 Jul;6(7):1215-20. doi: 10.1097/JTO.0b013e318219aaae.
4
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.一种用于自动评估乳腺癌中Ki-67表达的虚拟显微镜应用程序的开发与评估
BMC Clin Pathol. 2011 Jan 25;11:3. doi: 10.1186/1472-6890-11-3.
5
Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.基因组和功能分析鉴定 CRKL 为肺癌中扩增的癌基因。
Oncogene. 2010 Mar 11;29(10):1421-30. doi: 10.1038/onc.2009.437. Epub 2009 Dec 7.
6
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.正常细胞和癌细胞中c-Abl酪氨酸激酶的细胞质信号传导
Biol Cell. 2008 Nov;100(11):617-31. doi: 10.1042/BC20080020.
7
Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response.趋化因子受体在癌症转移中的作用以及癌细胞衍生趋化因子在宿主免疫反应中的作用。
Cancer Sci. 2007 Nov;98(11):1652-8. doi: 10.1111/j.1349-7006.2007.00606.x.
8
Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene.含CCL19[趋化因子（C-C基序）配体19]基因的阳离子脂质体偶联腺病毒的抗肿瘤活性
Biotechnol Appl Biochem. 2007 Oct;48(Pt 2):109-16. doi: 10.1042/ba20070038.
9
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.功能性CCR7趋化因子受体的表达可抑制恶性小鼠乳腺癌细胞转移的血管内侵入后步骤。
Oncol Rep. 2007 Aug;18(2):451-6.
10
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.生长因子和趋化因子受体的表达：炎性乳腺癌生物学的新见解
Ann Oncol. 2007 Jun;18(6):1021-9. doi: 10.1093/annonc/mdm060. Epub 2007 Mar 9.